Investment Rating - The report maintains a "Buy" rating for China Xuyang (1907.HK) with a target price of HKD 4.2, indicating a potential upside of 68% from the current stock price of HKD 2.5 [1][6][13]. Core Views - Despite the cyclical downturn, China Xuyang managed to achieve profitability in the first half of 2025, with total revenue of RMB 20.549 billion, a year-on-year decrease of 18.5%, and a net profit of RMB 0.87 billion, down 34% primarily due to falling coke prices [1][2][4]. - The company demonstrated strong cost control capabilities, achieving a gross margin of 11.9%, which is an increase of 4.4 percentage points year-on-year, attributed to effective cost-saving measures and a reduction in depreciation expenses [2][3]. - The report anticipates continued low volatility in coke prices for the next six months, with the average price per ton expected to stabilize around RMB 1,500 [2]. Financial Performance Summary - Coke and Coking Business: Revenue for the coke and coking segment was RMB 6.36 billion, down 35.2% year-on-year, with an average selling price of approximately RMB 1,400 per ton, a decrease of about 30% [2]. - Chemical Business: Revenue from the chemical segment fell to RMB 9.1 billion, a decline of 12.6%, primarily due to lower average prices for key products [3]. - Operating Management: Revenue from operating management dropped to RMB 1.275 billion, a decrease of 47%, mainly due to the completion of agreements for three projects [3]. - Trade Business: Trade revenue increased by 53% to RMB 3.73 billion, driven by higher trading volumes, although it reported a pre-tax loss of RMB 184 million [3]. Profit Forecasts - The report revises the net profit forecasts for 2025, 2026, and 2027 to RMB 1.7 billion, RMB 4.8 billion, and RMB 10.6 billion respectively, down from previous estimates of RMB 2.3 billion, RMB 7.8 billion, and RMB 11.5 billion [1][4]. - Corresponding EPS estimates are adjusted to HKD 0.04, HKD 0.12, and HKD 0.26 for the years 2025, 2026, and 2027 respectively [1][4]. Valuation Analysis - The valuation is based on both comparable company analysis and DCF methods, with a target price of HKD 4.2 derived from a PE multiple of 40x applied to the 2026 EPS [12][13]. - The DCF analysis estimates a market value of HKD 19.45 billion, reflecting the company's resilience and growth potential despite current industry challenges [12][13].
中国旭阳集团（01907）：周期低点仍实现盈利